Homepage Top Section2

Taltz met the primary and all key secondary endpoints in the late-stage trial, called COAST-X. The 52-week trial evaluated the safety and efficacy of the psoriatic arthritis drug

Keytruda is an anti-PD-1 therapy, while Inlyta is a tyrosine kinase inhibitor. Keytruda will help enhance the ability of the body’s immune system to detect and combat tumor

Under the three-year deal, the partnership will use insitro’s platform to create disease models for NASH and discover targets that can impact clinical progression and regression of the

Paragon Bioservices is a major viral vector development and manufacturing partner for gene therapies. Paragon president and CEO Pete Buzy said: “We are excited to join forces with

The company said that it used a priority review voucher to fast track the review of the regulator on brolucizumab in order to make it available to patients

Balversa is now indicated in the US for the treatment of adult patients having locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration

The investment in AskBio includes an amount of $225m committed by global alternative asset firm TPG Capital and life sciences investment firm Vida Ventures in exchange of a

The latest approval for Lynparza in Europe is for its use as a monotherapy for adult patients with germline BRCA1/2-mutations (gBRCAm), and who have human epidermal growth factor

Evenity is a bone-building humanized monoclonal antibody developed to inhibit the activity of sclerostin. It is claimed to be the only bone builder that simultaneously increases bone formation